- Home
- OPRT vs MNPR Comparison
OPRT vs MNPR Comparison
Compare OPRT & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRT
- MNPR
- Stock Information
- Founded
- OPRT 2005
- MNPR 2014
- Country
- OPRT United States
- MNPR United States
- Employees
- OPRT N/A
- MNPR N/A
- Industry
- OPRT Finance: Consumer Services
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- OPRT Finance
- MNPR Health Care
- Exchange
- OPRT Nasdaq
- MNPR Nasdaq
- Market Cap
- OPRT 110.7M
- MNPR 95.5M
- IPO Year
- OPRT 2019
- MNPR 2019
- Fundamental
- Price
- OPRT $3.10
- MNPR $18.09
- Analyst Decision
- OPRT Buy
- MNPR Strong Buy
- Analyst Count
- OPRT 4
- MNPR 3
- Target Price
- OPRT $5.17
- MNPR $27.33
- AVG Volume (30 Days)
- OPRT 142.8K
- MNPR 1.5M
- Earning Date
- OPRT 11-12-2024
- MNPR 11-08-2024
- Dividend Yield
- OPRT N/A
- MNPR N/A
- EPS Growth
- OPRT N/A
- MNPR N/A
- EPS
- OPRT N/A
- MNPR N/A
- Revenue
- OPRT $796,905,000.00
- MNPR N/A
- Revenue This Year
- OPRT N/A
- MNPR N/A
- Revenue Next Year
- OPRT $5.58
- MNPR N/A
- P/E Ratio
- OPRT N/A
- MNPR N/A
- Revenue Growth
- OPRT N/A
- MNPR N/A
- 52 Week Low
- OPRT $2.05
- MNPR $1.37
- 52 Week High
- OPRT $4.60
- MNPR $38.50
- Technical
- Relative Strength Index (RSI)
- OPRT 61.04
- MNPR 60.19
- Support Level
- OPRT $2.82
- MNPR $16.26
- Resistance Level
- OPRT $3.32
- MNPR $19.70
- Average True Range (ATR)
- OPRT 0.22
- MNPR 2.15
- MACD
- OPRT 0.04
- MNPR -0.07
- Stochastic Oscillator
- OPRT 72.97
- MNPR 74.36
About OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.